Xtant Medical Holdings, Inc.

Xtant Medical Holdings, Inc. announced its Annual Meeting of Stockholders will be held on August 7, 2026, in New York. Stockholders will vote on the election of six director nominees, the ratification of Grant Thornton LLP as the independent registered public accounting firm for the year ending December 31, 2026, and an advisory resolution on executive compensation. The record date for stockholders entitled to vote is June 9, 2026.

Xtant Medical reported a significant decline in Q1 2026 revenue to $20.88 million, down from $32.90 million in Q1 2025, resulting in a net loss of $3.09 million compared to a net income of $0.06 million in the prior year. The company received $8.5 million from the Companion Spine Note and $2.2 million in working capital settlement related to the Coflex/CoFix assets and international hardware business divestitures completed in December 2025. These divestitures contributed to the absence of license revenue in Q1 2026.

Xtant Medical Holdings, Inc. reported a Q1 2026 net loss of $3.1 million on revenue of $20.9 million, a decline from Q1 2025 due to asset sales and non-recurring license revenue. Despite the Q1 financial performance, the company significantly strengthened its balance sheet by reducing total indebtedness by $13.3 million. Xtant Medical also announced an exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bellows product and launched Trivium™ Shaped, leading to an increase in full-year 2026 revenue guidance to a range of $101-$105 million.

Xtant Medical Holdings, Inc. announced an exclusive distribution agreement with Dilon Technologies, Inc. for the HEMOBLAST® Bellows product in the United States. This FDA-approved topical surgical hemostatic agent will be marketed and sold by Xtant, which has also hired approximately 20 Dilon sales personnel to facilitate its distribution. Dilon will continue manufacturing the product in France.